Posters & Publications
2017
BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.
Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09.
SARA clinical program for evaluating safety and efficacy of Sarconeos in a Phase 2b clinical trial. Dioh et al. Poster presentation at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy.
Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1073-1074. Abstract 9-02
Sarconeos, a drug candidate in clinical development for Sarcopenia, demonstrates sharp functional improvement and anti-fibrotic properties in an animal model of Duchenne muscular dystrophy. Dilda et al. Poster presentation at the 22nd International Annual Congress of the World Muscle Society (WMS), October 3-7, 2017, Saint Malo, France.
BIO103, a second-generation compound for the treatment of sarcopenia. From anabolic properties to the reversion of aging-related functional loss. Dilda et al. Poster presentation at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.
Abstract published in The Journal of Frailty & Aging. 6(S1), 146, Abstract 217.
SARA-PK: A single and multiple ascending oral doses study to assess the safety and evaluate the pharmacokinetics of BIO101 in healthy young and older volunteers. Dioh et al. Oral and poster presentations at the 8th International Conference on Frailty & Sarcopenia Research (ICFSR), April 27-29, 2017, Barcelona, Spain.
Abstract published in The Journal of Frailty & Aging. 6(S1), 28, Abstract OC38.